NCT05973006: Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines |
|
|
| Completed | 3 | 400 | US | NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine, NVX-CoV2601, Prototype/XBB.1.5 Bivalent Vaccine (5 µg), Omicron XBB.1.5 (sub-variant)SARS-CoV-2 rS /Matrix-M Adjuvant | Novavax | COVID-19 | 04/24 | 09/24 | | |
